Spectrum Falls After Bladder Cancer Drug Fails in Study

Spectrum Pharmaceuticals Inc. plunged the most in eight months after its experimental bladder cancer drug apaziquone failed to prevent tumors from recurring in two studies.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.